Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Epogen epoetin alfa regulatory update

AMGN said that it is in discussions with FDA to update safety information on the labels of all erythropoiesis-stimulating agents (ESAs) based on recent Phase III data in high-hemoglobin target studies of Aranesp darbepoetin

Read the full 344 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE